Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancerDelfina Popiel, Jerzy Pieczykolan|Frontiers in Oncology|2024Cited by 5